Figure 1
Figure 2
Figure 3
Figure 4
![Local tumor recurrence-free rate according to the range of the embolization for transcatheter arterial chemoembolization (TACE). The cumulative 3-, 6-, 12-month tumor local recurrence rates were 2.8%, 2.8%, 8.3%, respectively, for cases with embolization of the entire corona enhancement area, and 20.8%, 45.8%, 75%, respectively, for cases without embolization of the entire corona enhancement area (hazard ratio [HR], 0.079; 95% confidence interval [CI], 0.026–0.24; p < 0.001).](https://sciendo-parsed.s3.eu-central-1.amazonaws.com/647356294e662f30ba53aaf0/j_raon-2021-0047_fig_004.jpg?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Credential=ASIA6AP2G7AKPENEKDWC%2F20260118%2Feu-central-1%2Fs3%2Faws4_request&X-Amz-Date=20260118T230721Z&X-Amz-Expires=3600&X-Amz-Security-Token=IQoJb3JpZ2luX2VjELr%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaDGV1LWNlbnRyYWwtMSJHMEUCIA4NzPlHb1AaA1eYYheoUwpZN9yNaqCvb%2Ft8zU%2BXcCzNAiEA1GIVeVz3CSCabUDq%2F8l7NhrvwGPgo3DwIBO6dWdXeO4qxgUIg%2F%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FARACGgw5NjMxMzQyODk5NDAiDOuqNxbeWW2LkYKaliqaBUjzhwEljSmWgNQ54MBzMfpX6g5tdWWC4cgk4rtwwAmpnGgh4G5S5bJ%2Fg1xaJO0U2D48HUR07nuoFrd5FmfWfxGHU7J9k1nykiIapuB4cQ5PWdJaj%2BMRVkhpgSu48rmfpeR4spr8D3pMvC7pf1Yuyrmp3vJN3T52Nz6b%2B6GPQNsbgg4TQTPDoKtzx8ENnOtw9WKfIP1CviUUe2akVh%2Bz2glKni982005a%2BVygnkryxLNVuRZHzeDtesDTPAm2DzbBWLoR4DuC8Pac4ruujS4aDvHPMW1qmBtw10la1zwXrFS2MJ%2Ben%2F6WNkHmT%2B0MbzL7aup2Y67sV02P8Tyoeu23gahkzBhStXwqKYkO66LFaMi0NB6lwuqlT04Awl4ZiVLvhkaCv0O9TejFJCv5anugCXHe3YRHSaLoAWMuEO3CFeYGuMB3wh%2BBBQFz433zFfUxV95ZCZO8v1mala9JvfUMy2Wp7bRMMFrSfCqx%2FVDtchUDlMQgsh7raZNJoSimdhmdB4TX47CX%2FW45iJwGLsA8j%2BUEnU%2FjeaDoXawyKXgbeubq21cL%2F5%2BFMCiVq1RSHNuS5ttkqW0wVWdmwU9%2F7sI3pnd8UhajBvbIKGE0WrXvEN7yd8F%2F1smg4aKqswTfotGree2biFxn61eU17tX%2B28stm0jhHf0jG7%2BM%2FDuATPdqwriHxNxZfnrkgJw4MJZQEQj9jej3oQ24FjidI2MJP4Z36gB0HnYpPrOOGc3DvKtGAvnImWE%2Fk9D6Kx37mOZGWx%2BqkGqS92NCsIsrQs%2FXM9NtjuhrExhVdbzH%2F%2FTz9tAkNGnVHoWXU9xlK6oBZlK%2BcVwI4wkAZjpW8UiUM%2BTTrP7naEYfW%2FqDDSGg1A%2FHN92IM1C7FbqRoqCOV6mDDlubTLBjqxAbx17pYWOtcHw5bEC6M99X6t1W7GCcov%2BueKK7rwbbLylvgcgFn4RuXiezcqJQwRiDhdSQs1GacS9F7ZRNHHUNN7vEY%2B9PQYH88z5pbfuHk3NHAb65PRKMCnt3pB%2FQ3Brz%2BrD%2BrF2gYLRzaldbK3JJlEIDvRr1Gjmu%2FajSAVKUET0f%2FzMnALXCOXh%2FOxEQ1K95RIpe7hXzZHyhoJB2B9%2FsgCDDc1eOFp5pF3oAtD7KR4cQ%3D%3D&X-Amz-Signature=09c9ae7412f5a86c6fc69fdf27d98673a2a0fa9ee23319d3d308cad48017fdbe&X-Amz-SignedHeaders=host&x-amz-checksum-mode=ENABLED&x-id=GetObject)
Clinical characteristics of nodules in group A and B
| Clinical characteristics | Group A (n = 36) | Group B (n = 24) | p value |
|---|---|---|---|
| Age, years* | 74 (70–79) | 71 (64–79) | 0.149 |
| Gender, male/female | 8/28 | 6/18 | 0.999 |
| Etiology (HCV/HBV/Alcohol/Unknown) | 16/8/8/4 | 9/5/6/4 | 0.912 |
| Child-Pugh classification (A/B) | 31/5 | 19/5 | 0.569 |
| BCLC stage(0/A/B) | 11/20/5 | 5/17/2 | 0.545 |
| Size of tumor, mm* | 14.5 (12–21.3) | 15.5 (11–22) | 0.757 |
| Thickness of corona enhancement(≤ 2mm/>2mm) | 17/19 | 10/14 | 0.793 |
| AFP, ng/ml* | 4.9 (2.6–10.6) | 5.9 (2.7–14.1) | 0.419 |
| DCP, mAU/mL* | 26.4 (17.0–49.2) | 48.8 (25.3–153.9) | 0.021 |
| Usage of miriplatin, mg* | 28 (20–38.5) | 30 (22.4–51.5) | 0.310 |
Univariate and multivariate logistic regression analysis for factor affecting local tumor recurrence
| Factor | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| Odds ratio (95% CI) | p value | Odds ratio (95% CI) | p value | |
| Size of tumor (< 20 vs. ≥ 20 mm) | 0.67 (0.20–2.32) | 0.577 | ||
| AFP (< 10 vs. ≥ 10 ng/mL) | 0.45 (0.13–1.61) | 0.242 | ||
| DCP (< 40 vs. ≥ 40 mAU/mL) | 0.59 (0.18–1.92) | 0.417 | ||
| Usage of miriplatin (< 30 vs. ≥ 30 mg) | 0.70 (0.17–1.89) | 0.420 | ||
| Thickness of corona enhancement (≤ 2mm/ > 2mm) | 0.97 (0.30–3.20) | 0.999 | ||
| Degree of iodized oil accumulation (Group A vs. B) | 0.045 (0.0080–0.20) | < 0.001 | 0.042 (0.010–0.17) | < 0.001 |